Literature DB >> 24342805

Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses.

Halina M Trist1, Peck Szee Tan, Bruce D Wines, Paul A Ramsland, Eva Orlowski, Janine Stubbs, Elizabeth E Gardiner, Geoffrey A Pietersz, Stephen J Kent, Ivan Stratov, Dennis R Burton, P Mark Hogarth.   

Abstract

Little is known of the impact of Fc receptor (FcR) polymorphism in macaques on the binding of human (hu)IgG, and nothing is known of this interaction in the pig-tailed macaque (Macaca nemestrina), which is used in preclinical evaluation of vaccines and therapeutic Abs. We defined the sequence and huIgG binding characteristics of the M. nemestrina activating FcγRIIa (mnFcγRIIa) and inhibitory FcγRIIb (mnFcγRIIb) and predicted their structures using the huIgGFc/huFcγRIIa crystal structure. Large differences were observed in the binding of huIgG by mnFcγRIIa and mnFcγRIIb compared with their human FcR counterparts. MnFcγRIIa has markedly impaired binding of huIgG1 and huIgG2 immune complexes compared with huFcγRIIa (His(131)). In contrast, mnFcγRIIb has enhanced binding of huIgG1 and broader specificity, as, unlike huFcγRIIb, it avidly binds IgG2. Mutagenesis and molecular modeling of mnFcγRIIa showed that Pro(159) and Tyr(160) impair the critical FG loop interaction with huIgG. The enhanced binding of huIgG1 and huIgG2 by mnFcγRIIb was shown to be dependent on His(131) and Met(132). Significantly, both His(131) and Met(132) are conserved across FcγRIIb of rhesus and cynomolgus macaques. We identified functionally significant polymorphism of mnFcγRIIa wherein proline at position 131, also an important polymorphic site in huFcγRIIa, almost abolished binding of huIgG2 and huIgG1 and reduced binding of huIgG3 compared with mnFcγRIIa His(131). These marked interspecies differences in IgG binding between human and macaque FcRs and polymorphisms within species have implications for preclinical evaluation of Abs and vaccines in macaques.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24342805      PMCID: PMC4080885          DOI: 10.4049/jimmunol.1301554

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Expression of the high responder/non-responder human Fc gamma RII. Analysis by PCR and transfection into FcR-COS cells.

Authors:  B J Tate; E Witort; I F McKenzie; P M Hogarth
Journal:  Immunol Cell Biol       Date:  1992-04       Impact factor: 5.126

Review 2.  Clinical relevance of Fc gamma receptor polymorphisms.

Authors:  A Rascu; R Repp; N A Westerdaal; J R Kalden; J G van de Winkel
Journal:  Ann N Y Acad Sci       Date:  1997-04-05       Impact factor: 5.691

3.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

4.  Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus.

Authors:  S V Joag; Z Li; C Wang; L Foresman; F Jia; E B Stephens; W Zhuge; O Narayan
Journal:  AIDS Res Hum Retroviruses       Date:  1999-03-01       Impact factor: 2.205

5.  Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. Enhancement and ablation of binding by site-directed mutagenesis.

Authors:  M D Hulett; E Witort; R I Brinkworth; I F McKenzie; P M Hogarth
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

6.  Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients.

Authors:  A J Duits; H Bootsma; R H Derksen; P E Spronk; L Kater; C G Kallenberg; P J Capel; N A Westerdaal; G T Spierenburg; F H Gmelig-Meyling
Journal:  Arthritis Rheum       Date:  1995-12

7.  Chimeric Fc receptors identify immunoglobulin-binding regions in human Fc gamma RII and Fc epsilon RI.

Authors:  M D Hulett; I F McKenzie; P M Hogarth
Journal:  Eur J Immunol       Date:  1993-03       Impact factor: 5.532

8.  Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections.

Authors:  L A Sanders; J G van de Winkel; G T Rijkers; M M Voorhorst-Ogink; M de Haas; P J Capel; B J Zegers
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 5.226

9.  Multiple regions of human Fc gamma RII (CD32) contribute to the binding of IgG.

Authors:  M D Hulett; E Witort; R I Brinkworth; I F McKenzie; P M Hogarth
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

10.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

Authors:  P A Warmerdam; J G van de Winkel; A Vlug; N A Westerdaal; P J Capel
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

View more
  19 in total

Review 1.  The role of Fc receptors in HIV infection and vaccine efficacy.

Authors:  Sarah L Cocklin; Joern E Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

Review 2.  Survivors Remorse: antibody-mediated protection against HIV-1.

Authors:  George K Lewis; Marzena Pazgier; Anthony L DeVico
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

3.  IgG Binding Characteristics of Rhesus Macaque FcγR.

Authors:  Ying N Chan; Austin W Boesch; Nana Y Osei-Owusu; Ali Emileh; Andrew R Crowley; Sarah L Cocklin; Samantha L Finstad; Caitlyn H Linde; Rebecca A Howell; Isaac Zentner; Simon Cocklin; Adam R Miles; Joshua W Eckman; Galit Alter; Joern E Schmitz; Margaret E Ackerman
Journal:  J Immunol       Date:  2016-08-24       Impact factor: 5.422

4.  Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Authors:  Ariola Bardhi; Yanling Wu; Weizao Chen; Wei Li; Zhongyu Zhu; Jian Hua Zheng; Hing Wong; Emily Jeng; Jennifer Jones; Christina Ochsenbauer; John C Kappes; Dimiter S Dimitrov; Tianlei Ying; Harris Goldstein
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

5.  IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.

Authors:  Austin W Boesch; Adam R Miles; Ying N Chan; Nana Y Osei-Owusu; Margaret E Ackerman
Journal:  MAbs       Date:  2017-01-05       Impact factor: 5.857

6.  Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity.

Authors:  Doan C Nguyen; Rashesh Sanghvi; Franco Scinicariello; Joanna Pulit-Penaloza; Nicole Hill; Roberta Attanasio
Journal:  Immunogenetics       Date:  2014-05-09       Impact factor: 2.846

7.  Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.

Authors:  Diane L Bolton; Amarendra Pegu; Keyun Wang; Kathleen McGinnis; Martha Nason; Kathryn Foulds; Valerie Letukas; Stephen D Schmidt; Xuejun Chen; John Paul Todd; Jeffrey D Lifson; Srinivas Rao; Nelson L Michael; Merlin L Robb; John R Mascola; Richard A Koup
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

Review 8.  Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.

Authors:  Bruce D Wines; Hugh Billings; Milla R Mclean; Stephen J Kent; P Mark Hogarth
Journal:  Curr HIV Res       Date:  2017       Impact factor: 1.581

9.  Functional Interactions of Common Allotypes of Rhesus Macaque FcγR2A and FcγR3A with Human and Macaque IgG Subclasses.

Authors:  Michael W Grunst; Andres G Grandea; Sanath Kumar Janaka; Iman Hammad; Parker Grimes; Julie A Karl; Roger Wiseman; David H O'Connor; David T Evans
Journal:  J Immunol       Date:  2020-11-18       Impact factor: 5.422

10.  Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

Authors:  Randi B Gombos; Ana Gonzalez; Mariana Manrique; Dhan Chand; David Savitsky; Benjamin Morin; Ekaterina Breous-Nystrom; Christopher Dupont; Rebecca A Ward; Cornelia Mundt; Benjamin Duckless; Hao Tang; Mark A Findeis; Andrea Schuster; Jeremy D Waight; Dennis Underwood; Christopher Clarke; Gerd Ritter; Taha Merghoub; David Schaer; Jedd D Wolchok; Marc van Dijk; Jennifer S Buell; Jean-Marie Cuillerot; Robert Stein; Elise E Drouin; Nicholas S Wilson
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.